Last reviewed 2026-05-31 · How we verify

AZD9567 Monohydrat

AstraZeneca · Phase 1 active Small molecule ✓ Verified May 2026 Quality 10/100

AZD9567 Monohydrat is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

AZD9567 Monohydrate is a small molecule with the synonyms MIZACORAT. It is being studied in a Phase I clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AZD9567 Monohydrat
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Chest pain
Feeling hot
Vessel puncture site pain
Nasopharyngitis
Oral herpes
Dizziness
Hot flush
Nausea
Hyperhidrosis

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AZD9567 Monohydrat CI brief — competitive landscape report
AZD9567 Monohydrat updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about AZD9567 Monohydrat

What is AZD9567 Monohydrat?

AZD9567 Monohydrat is a Small molecule drug developed by AstraZeneca.

Who makes AZD9567 Monohydrat?

AZD9567 Monohydrat is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is AZD9567 Monohydrat in?

AZD9567 Monohydrat is in Phase 1.

What are the side effects of AZD9567 Monohydrat?

Common side effects of AZD9567 Monohydrat include Chest pain, Feeling hot, Vessel puncture site pain, Nasopharyngitis, Oral herpes, Dizziness.

Manufacturer: AstraZeneca — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing